



ASX Announcement

BOARD COMPOSITION CHANGES

MEDLAB CLINICAL LTD
A.C.N. 169 149 071
("Medlab" or "THE COMPANY")

Sydney, March 27, 2024 – Medlab Clinical Ltd (ASX:MDC) ("Medlab" or "the Company") is releasing the following update to stakeholders.

With a view to maximising value from a future transaction, changes have been made to the composition of Medlab's Board which reinforces its strategic credential in dealing with a transaction of this nature.

The process may involve engagement with current and new investors, as well as interested parties to achieve the ongoing success of the Company.

Resignations

Medlab advises that Dr Sean Hall (Chairman) and Mr. Michael Carter (Non-Executive Director) have recently resigned from the Company's board.

Medlab expresses gratitude to both Sean and Michael for their time and diligent efforts in managing the Company on a care-taker mode, since Company entered trading suspension.

Appointments

Medlab is pleased to announce the appointment of Mr Edmond Tan and Mr Tim Walker to the Company's Board as Non-Executive Directors.

Edmond Tan is a financial services professional with over 10 years' experience in various roles which include Private Wealth Management, Family Office, and Structured Finance. In addition, he was involved in the establishment of a mid-market private equity joint venture fund with a specific focus on foreign investment into Australia. Currently, Edmond is a Director of Regenerate Pty Ltd a rare earth magnet recycling technology based in Houston, Texas. He is also the Australian Representative for Obsidian Global Partners LLC, a structured financier for ASX listed companies. Edmond holds a Bachelor of Commerce from Curtin University.

Tim Walker is a corporate finance professional with extensive experience in originating, managing, and leading a variety resource-focused transaction. Specifically, specialising in M&A transactions across the Canadian and Australian markets, IPOs, and both equity and debt financing solutions. Tim's past directorships with exploration companies have provided him with a breadth of experience across various commodity groups, including lithium exploration, rare earth and niobium hosted carbonatite deposits, whilst also having experience transacting on iron ore and base metal projects. Tim holds a Bachelor of Commerce from the University of Western Australia and a Certificate in Geology.

As per ASX listing rule 3.16, the Company was required to immediately notify the market. The Company will ensure future adherence to this listing rule is prioritised.

-ENDS-

Announcement authorised by Medlab Clinical Ltd Board of Directors

NOTE:

Dear MDC Shareholders, if you held securities as at 12 Jan 2024, subsequent to the EGM held on 22 Dec 2023, you are asked to please update your details (Email and Banking) by using the form provided at <https://www.medlab.group/royalty-holders> as you may be entitled to future royalty payments.